NewAmsterdam Pharma Corporation

📍 Aventura, United States🗓 Founded 2019👥 67 employees💰 Last funded Jul 2024
Biotechnology🌐 newamsterdampharma.com
Website LinkedIn
This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.
2
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Netherlands
1
Frequently asked questions
Who invested in NewAmsterdam Pharma Corporation?
NewAmsterdam Pharma Corporation has 2 investors on record on gritt.io, 1 mid-stage.
When did NewAmsterdam Pharma Corporation last raise funding?
The most recent investment in NewAmsterdam Pharma Corporation recorded on gritt.io was in July 2024.
When was NewAmsterdam Pharma Corporation founded?
NewAmsterdam Pharma Corporation was founded in 2019.
What industry is NewAmsterdam Pharma Corporation in?
NewAmsterdam Pharma Corporation operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is NewAmsterdam Pharma Corporation based?
NewAmsterdam Pharma Corporation is headquartered in Aventura, United States.